Drug Trial Radar · NCT03755778
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jun 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 29, 2018
Primary completion
Jan 21, 2019
Study completion Jan 27, 2019
Sponsor
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Pharmaceutical Research Associates
- First posted
- Nov 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Conditions
- RSV Infection
Interventions
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
EDP-938Drug
Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
ItraconazoleDrug
Subjects will receive itraconazole once daily from Day 5 to Day 18
RifampinDrug
Subjects will receive rifampin once daily from Day 5 to Day 16
QuinidineDrug
Subjects will receive quinidine once daily from Day 5 to Day 12
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of EDP-938 with and without coadministration with itraconazoleTime frame: Up to 19 days
- AUC of EDP-938 with and without coadministration with itraconazoleTime frame: Up to 19 days
- Cmax of EDP-938 with and without coadministration with rifampinTime frame: Up to 17 days
- AUC of EDP-938 with and without coadministration with rifampinTime frame: Up to 17 days
- Cmax of EDP-938 with and without coadministration with quinidineTime frame: Up to 13 days
- AUC of EDP-938 with and without coadministration with quinidineTime frame: Up to 13 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaceutical Research Associates, Inc.,
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.